Literature DB >> 14709647

The interleukin-6 G(-174)C promoter polymorphism does not determine plasma interleukin-6 concentrations in experimental endotoxemia in humans.

Georg Endler1, Claudia Marsik, Christian Joukhadar, Rodrig Marculescu, Florian Mayr, Christine Mannhalter, Oswald F Wagner, Bernd Jilma.   

Abstract

BACKGROUND: Interleukin 6 (IL-6) is a pleiotropic cytokine that plays an essential role in the pathogenesis of acute and chronic infections. As the role of the IL-6 G(-174)C polymorphism in determining serum concentrations of IL-6 is controversial, we studied the genotype-specific IL-6 response in a well-standardized model of systemic inflammation.
METHODS: A total of 76 healthy young males (age range, 19-35 years) received a single bolus of 2 ng/kg endotoxin [lipopolysaccharide (LPS)] intravenously. Plasma IL-6 was measured by enzyme immunoassay at 0, 2, 6, and 24 h after LPS infusion, and the IL-6 promoter genotype was analyzed by a mutagenic separated PCR assay.
RESULTS: IL-6 increased 300-fold 2 h after LPS challenge and returned almost to normal within 24 h. Neither basal IL-6 nor the IL-6 response to LPS was significantly affected by the IL-6 promoter genotype.
CONCLUSIONS: The IL-6 G(-174)C promoter polymorphism does not significantly influence basal concentrations of IL-6 or peak IL-6 in human endotoxemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14709647     DOI: 10.1373/clinchem.2003.022459

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  6 in total

Review 1.  Human experimental endotoxemia in modeling the pathophysiology, genomics, and therapeutics of innate immunity in complex cardiometabolic diseases.

Authors:  Parth N Patel; Rhia Y Shah; Jane F Ferguson; Muredach P Reilly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-12-30       Impact factor: 8.311

2.  Melphalan exposure induces an interleukin-6 deficit in bone marrow stromal cells and osteoblasts.

Authors:  Stephanie L Rellick; Debbie Piktel; Cheryl Walton; Brett Hall; William Petros; James E Fortney; Marieta Gencheva; Jim Denvir; Gerald Hobbs; Michael Craig; Laura F Gibson
Journal:  Cytokine       Date:  2012-02-21       Impact factor: 3.861

3.  The inflammatory response is influenced by FXIII VAL 34 LEU polymorphism in a human LPS model.

Authors:  Florian M Kovar; Claudia L Marsik; Bernd Jilma; Christine Mannhalter; Christian Joukhadar; Oswald F Wagner; Georg Endler
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

4.  Common studied polymorphisms do not affect plasma cytokine levels upon endotoxin exposure in humans.

Authors:  S Taudorf; K S Krabbe; R M G Berg; K Møller; B K Pedersen; H Bruunsgaard
Journal:  Clin Exp Immunol       Date:  2008-02-25       Impact factor: 4.330

5.  Interleukin-6 gene polymorphisms in Egyptian children with febrile seizures: a case-control study.

Authors:  Seham F Azab; Mohamed A Abdalhady; Alshaymaa Ali; Ezzat K Amin; Dina T Sarhan; Eman M Elhindawy; Mohamed A A Almalky; Ahmed A Elhewala; Mohamed M A Salam; Mustafa I A Hashem; Attia A Soliman; Nagwa E Akeel; Sawsan H Abdellatif; Sanaa M Ismail; Nahla A Elsamad; Manal S Arafat; Anwar A Rass; Maha A A Basset
Journal:  Ital J Pediatr       Date:  2016-03-09       Impact factor: 2.638

6.  A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy.

Authors:  Srinivasan Beddhu; Rebecca Filipowicz; Bin Wang; Guo Wei; Xiaorui Chen; Abinash C Roy; Scott L DuVall; Hanadi Farrukh; Arsalan N Habib; Terrence Bjordahl; Debra L Simmons; Mark Munger; Greg Stoddard; Donald E Kohan; Tom Greene; Yufeng Huang
Journal:  Can J Kidney Health Dis       Date:  2016-12-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.